Where Are The Positives? Sarepta Therapeutics Inc (NASDAQ:SRPT), PositiveID Corp (PSID) and Amarantus Bioscience Holdings Ltd (AMBS)

Posted by admin April 7, 2015 0 Comment 761 views


New York, NY – GDP INSIDER  –  04/07/2015.

This article discusses three companies: Sarepta Therapeutics Inc (NASDAQ:SRPT), PositiveID Corp (OTCMKTS:PSID) and Amarantus Bioscience Holdings Ltd (OTCBB:AMBS)

Sarepta Therapeutics Inc (NASDAQ:SRPT) continued its recent upward trend with the stock gaining 3.37% or $0.48 to close the day at a closing price of $14.73 on unusual trading volume of 1.413 million, compared to its three month average trading volume of 0.846 million. The US-based biopharmaceutical company has been doing well so far this year with the stock up 1.80%, compared to the S&P500 which is up 1.05% for the same period. The RSI of 60.50 indicates the stock is not overvalued at the current levels, the MFI of 61.61 shows the money is flowing in the right direction, making it a hold for now.

Is It Now A Good Time To Invest In Sarepta Therapeutics Inc? Read Our Free SRPT Analysis To Know More.

PositiveID Corp (OTCMKTS:PSID) continued to gain yesterday with the stock climbing another 0.40% or $0.0001 to close at $0.0251 on heavy trading of 8.805 million shares, compared to its three month average trading volume of 3.286 million. The developer of biological detection and diagnostic solutions has seen its recent gains after it announced that it had successfully complete the phase II testing of its Firefly Dx prototype. The prototype allows one handheld device to detect up to four different pathogens simultaneously, providing a significant advancement on other similar devices, worth keeping an eye on this stock for the medium term.

Can PositiveID Corp Keep Gaining? Review The Financials With Our Free PSID Analysis

Amarantus Bioscience Holdings Ltd (OTCBB:AMBS) fell back again yesterday with the stock losing 13.33% or $0.0068 to close at $0.0442 on heavy trading of 8.921 million shares, compared to its three month average trading volume of 5.875 million. The development stage biotechnology company focused on treatments for various dysfunctions has been in decline recently and has lost 16.65% of its value so far this year. While the stock’s RSI of 29.54 could indicate that it is undervalued, its bearish diverging MACD tells a different story, making it a sell rather than hold for now.

Where Are The Positives In Amarantus Bioscience Holdings Ltd? Click Here For Free AMBS Analysis.

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment